Added to YB: 2026-05-05
Pitch date: 2026-04-30
LLY [bullish]
Eli Lilly and Company
+2%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$761.7B
Pitch Price
$948.95
Price Target
N/A
Dividend
0.74%
EV/EBITDA
21.92
P/E
30.24
EV/Sales
11.05
Sector
Pharmaceuticals
Category
growth
LLY Just Delivered a 28% EPS Beat
LLY (earnings): Q1 EPS $8.55 vs $6.66 est (28% beat), rev $19.8B vs $17.6B est (13% beat, 56% YoY). Mounjaro $8.66B (+125% YoY), Zepbound $4.1B (+79% YoY). Op margin 29%→45%. Raised FY26 guide to $82-85B rev, $35.50-37 EPS. Institutional sold 1,240 puts $785 strike exp 6/12/26 for $905K premium. At 21.7x fwd P/E on 50%+ growth, downside limited w/ no earnings until Aug 5.
Read full article (2 min)